Webinar Summary
- Integration of single-cell sequencing and spatial datasets to understand the biological insights of innate and acquired resistance to immunotherapy
- The identification of immune-striving phenotypes and the emergence of specific melanoma subclones post-therapy
- The role of B cell signatures and lymphoid aggregates in therapeutic outcomes
- Immune hotspot in melanoma patients treated with neoadjuvant immunotherapy
Attendees will gain a deeper understanding of how these discoveries can inform future therapeutic strategies and improve patient outcomes.
Heterogeneous resistance to immunotherapy remains a significant challenge in cancer treatment, driven by intrinsic genetic traits of the tumor and extrinsic factors within the tumor microenvironment (TME). Join us for an insightful webinar, where Dr. Camelia Quek presents on the innovative use of longitudinal multimodal single-cell analysis and spatial inference to uncover the complexities of the tumor microenvironment (TME) of advanced melanoma patients with innate resistance, acquired resistance, or response to immunotherapy.
Presenters
Camelia Quek
Dr. Camelia Quek is a CINSW Research Fellow at Melanoma Institute Australia and is appointed as an Honorary Senior Research Fellow at the University of Sydney. Dr Quek has training in both molecular biology and bioinformatics, where she originally did a first degree in molecular biology at the University of New South Wales before moving on to do a PhD in Neuroscience and Computational Biology at the University of Melbourne. Dr Quek has extensive experience in integrating cutting-edge techniques and sophisticated computation methods to solve clinically important questions that associate with strong clinical implementations. She is currently leading the Translational Bioinformatics and Data Analytics Program for cancer therapy studies that resulted in several key publications (e.g. Cancer Cell and Nature Publishing Group Journals) in identifying molecular determinants of response and resistance in patients with advanced melanoma treated with targeted and immune-based therapies. In 2017, she was part of the Melanoma Institute Australia research team that won the CINSW Premier’s Awards for Outstanding Cancer Research. In 2022, she was awarded the prestigious CINSW Wildfire Highly Cited Publication Award for her co-first author paper published in Cancer Cell. Her current research interests are: (1) Biomarkers of response and resistance to cancer therapies, (2) Single-cell multi-omics to understand treatment and progression, and (3) Spatial imaging to dissect key cellular interactions and novel drug targets.
Sponsor
Akoya Biosciences
Content Partners
Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.
